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A B S T R A C T
Preterm premature rupture of membranes (PPROM) occurs in 3 percent of all pregnancies and is responsible for, or
associated with, approximately one-third of preterm births causing significant perinatal morbidity and fetal death. Pre-
term infants are very vulnerable to respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), periventri-
cular leucomalacia (PVL), other neurological sequelae, infection and necrotizing enterocolitis (NEC). Chorioamnionitis
based on clinical criteria occurs in approximately 3–30% of all PPROM pregnancies. The aim of this study was to ana-
lyze the role of antibiotic prophylaxis in delivery delay on neonatal outcome (body weight, Apgar scores, pulmonary com-
plications, neurological complications – abnormal cerebral ultrasound scan prior to hospital discharge, perinatal infec-
tions) and to determine the possibility of an optimal antibiotic regimen. Therefore we retrospectively analyzed last 5 years
of data from patients treated in our center and provided a coherent overview of the clinical course and outcome of patients
with PPROM treated with prophylactic antibiotics and antenatal corticosteroids. There were 324 preterm newborns
which fulfilled the inclusion criteria for our study; 190 in Study group (received empiric i.v. antibiotics) and 134 in Con-
trol group (without antibiotic). We found significant difference in gestational age (p<0.0001), birth weight (p<0.0001),
Apgar scores (p<0.0001) maternal C-reactive protein level (p<0.0001) and latency period (5.54 days vs. 11.33 days,
p=0.001) between the groups. Histologic chorioamnionitis was significantly more frequent in s Study group (14.2% vs.
36.3%, p<0.0001). We found significant difference in neonatal outcome according the different antibiotic treatment. An-
tenatal antibiotics and corticosteroid therapies have clear benefits and should be offered to all women without contrain-
dications.
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Introduction
Premature rupture of membranes (PROM) is defined
as a rupture of amniotic membranes before the onset of
uterine contractions. Preterm PROM (PPROM) is the
term used when the pregnancy is less than 37 completed
weeks of gestation. PPROM occurs in 3 percent of all
pregnancies and is responsible for, or associated with, ap-
proximately one-third of preterm births causing signifi-
cant perinatal morbidity and fetal death. The manage-
ment of PPROM is among the most controversial issues
in perinatal medicine, especially regarding duration of
administration and type of antibiotic prophylaxis. The
fetus and neonate are at greater risk of PPROM related
morbidity and mortality then the mother. Majority of
pregnancies complicated with PPROM deliver preterm
and within one week of membrane rupture. The pathoge-
nesis of PPROM is not completely understood. Preterm
infants are very vulnerable to respiratory distress syn-
drome, intraventricular hemorrhage, periventricular
leucomalacia, other neurological sequelae, infection, and
necrotizing enterocolitis. The rates of these morbidities
are higher in the setting of chorioanionitis1. The risk of
placental abruption is seven to nine fold increased in
pregnancies with PPROM if infection is present2. The
risk of PPROM have generally been viewed as those of
infection in opposition to those of prematurity. Neonatal
sepsis is documented in less than 10%, and chorioamnio-
nitis based on clinical criteria occurs in approximately
3–30% of all PPROM pregnancies2. Subclinical infections
based on positive amniotic fluid culture or histologic in-
flammation of the umbilical cord or membranes is seen
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up to 80%2. The reoccurrence rate for PPROM is up to
30%. Progesterone therapy and bacterial vaginosis treat-
ment appears to be effective in reducing the risk of reoc-
currence preterm birth caused by PPROM3. The goal of
antibiotic therapy is to reduce the frequency of maternal
and fetal infection and to delay the onset of preterm la-
bor. As the oldest and largest third level maternity center
in Croatia, Department for Obstetrics and Gynecology,
University Hospital Centre Zagreb in year 2012 had 4159
deliveries, 359 newborns (7.9%) were preterms. Perina-
tal mortality rate was 3.6%o. Therefore we retrospec-
tively analyze last 5 years of data from patients treated
in our center and provided a coherent overview of the
clinical course and outcome of patients with PPROM
treated with prophylactic antibiotics and antenatal corti-
costeroids. Here we present conclusions regarding the la-
tency period, maternal and neonatal morbidity and mor-
tality in patients with PPROM. The aim of this study was
to analyze the role of antibiotic prophylaxis in delivery
delay on neonatal outcome (body weight, Apgar scores,
pulmonary complications, neurological complications –
abnormal cerebral ultrasound scan prior to hospital dis-
charge, perinatal infections) and to determine the possi-
bility of an optimal antibiotic regimen.
Materials and Methods
As a third level perinatal center, the neonatal inten-
sive care unit (NICU) of Department for Obstetrics and
Gynecology, University Hospital Centre Zagreb takes
care of over half preterm newborns in Croatia. The study
retrospectively analyzed all newborns born prior to 37
weeks of gestation from singleton pregnancies compli-
cated with PPROM from January 2008 until December
2012. Preterm newborns with fetal and chromosomal
anomalies and preterm newborns from pregnancies com-
plicated with preeclampsia, HELLP syndrome, gesta-
tional diabetes mellitus and chronic diseases were ex-
cluded from the study. PPROM was confirmed by clinical
examination and with Amnisure® test. Chorioamnionitis
was diagnosed if two or more findings were present: ma-
ternal fever <38°C, maternal tachycardia (>100/min),
uterine fundal tenderness, vaginal discharge and puru-
lent or foul amniotic fluid, fetal tachycardia (>160/min),
maternal leukocytosis >12x10/L and elevated levels of
C-reactive protein. Gestational age at delivery was deter-
mined as period from last menstrual period or from fetal
ultrasound findings. Tocolysis was started in both groups
until 34 weeks of gestation during which time cortico-
steroids were administered. Patients from Study group
received empiric i.v. antibiotics. Control group was with-
out antibiotic prophylaxis. Neonatal outcome parame-
ters included gestational age at birth, birth weight, Ap-
gar score, perinatal infection, abnormal brain ultrasound
findings, respiratory distress syndrome (RDS) and neo-
natal death. Diagnosis of perinatal infection was based
on clinical examination of the infant and laboratory find-
ings at 12 to 36 hours after birth such as white count, ab-
solute neutrophil count, immature neutrophil count, ab-
solute band count and C-reactive protein level. Diagnosis
of respiratory distress syndrome (RDS) was based on
clinical findings, low oxygen saturation, respiratory aci-
dosis and chest X-ray. Abnormal brain ultrasound find-
ings included intraventricular haemorrhage (IVH) and
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TABLE 1





Gestational age (weeks) 33.17±2.6 31.26±3.9 <0.0001
Birth weight (grams) 2048±597 1703±592 <0.0001
White blood cells mothers (109/L) 12.8±3.7 13.91±3.9 0.029
C-reactive protein (g/L) 11.87±21 21.74±25 <0.0001
Latency period (days) 5.54±10.75 11.33±14.09 0.001
Positive umbilical cord blood culture (%) 81.5 88.6 0.046
Perinatal infections (%) 56.7 65.8 0.153 NS
Sepsis (%) 4.5 10 0.050
Abnormal brain US (%) 6.7 IVH; 0 PVL 4.2 IVH; 3.1 PVL 0.067 NS
RDS (%) 20.1 27.4 0.086 NS
Antenatal corticosteroids (%) 64.9 92.1 0.029
Transport in utero (%) 36.6 53.7 0.002
Histologic chorioamnionitis (%) 14.2 36.3 <0.0001
Apgar 1st min (1–10) 6.79 7.95 <0.0001
Apgar 5th min (1–10) 8.00 8.84 <0.0001
Cervical smear Ureaplasma/Mycoplasma/ Chlamydia (%) 8 18 0.040
Neonatal death (%) 4.5 8.4 0.165
IVH– intraventricular haemorrhage; PVL – periventricular leukomalacia; RDS – respiratory distress syndrome
white matter damage. Intraventricular haemorrhage
was diagnosed following Volpe’s criteria and graded from
I to IV (gr I–IV). White matter damage included periven-
tricular leukomalacia (PVL). All preterm newborns are
treated in NICU. For statistical comparison of results be-
tween groups we used chi-square test and Mann-Whitney
test.
Results
There were 324 preterm newborns which fulfilled the
inclusion criteria for our study; 190 in Study group and
134 in Control group. Control group included newborns
prior to 37 weeks of gestation from singleton pregnancies
complicated with PPROM but without antibiotic prophy-
laxis during the latency period. Preterm newborns with
fetal and chromosomal anomalies and preterm newborns
from pregnancies complicated with preeclampsia,
HELLP syndrome, gestational diabetes mellitus and
chronic diseases were excluded from the control group.
Maternal and neonatal characteristics for all premature
newborns are shown in Table 1. We found significant dif-
ference in gestational age (33.17 weeks vs. 31.26 weeks,
p<0.0001), birth weight (2048 g vs. 1703 g, p<0.0001),
Apgar scores in 1st (6.79 vs. 7.95, p<0.0001) and 5th (8.00
vs. 8.84, p<0.0001)) minute, maternal white blood cells
count (12.8x109 vs. 13.91x109, p=0.029) and C-reactive
protein level (11.87 vs. 21.74, p<0.0001), latency period
(5.54 days vs. 11.33 days, p=0.001) and antenatal corti-
costeroid administration (64.9% vs. 92.1%, p=0.029) be-
tween the groups. Histologic chorioamnionitis was sig-
nificantly more frequent in Study group (14.2% vs. 36.3%,
p<0.0001), too. 10.8% preterm newbornshad extremely
low birth weight, and 57 newborns (19.7%) low birth
rate, with significant difference between the groups;
p<0.0001 (Figure 1) More extremely low gestational age
newborns were in Study group, too (Figure 1). We found
significantly longer latency period in Study group; p=
0.001 (Figure 2). More pregnancies from control group
finished within first 72 hours; p<0.01 (Table 2).
Type of antibiotic treatment had significant impact
on prolongation of pregnancy after PPROM (Figure 3).
We found significant difference in neonatal outcome ac-
cording the treatment option (Table 3). Antibiotic pro-
phylaxis regimen in pregnancies complicated with PPROM
varies considerably regarding the regional hospitals that
patients were transferred from.
Discussion
Preterm delivery accounts for 80% of perinatal mor-
tality and more than half of the long-term morbidity. Ef-
fective treatment relies on accurate diagnosis and de-
pends on gestational age. PPROM is associated with
significant maternal and neonatal morbidity and mortal-
ity from infection, umbilical cord compression, placental
abruption and preterm birth. Subclinical intrauterine in-
fection has been implicated as a major etiological factor
in the pathogenesis and subsequent maternal and neona-
tal morbidity associated with PPROM. In the past, man-
agement of women with PPROM was expectant, without
any medications. Several studies reported that the la-
tency period after PPROM was 1.5–4.6 days4–6, which is
comparable with our control group, but different from
our study group where latency period was prolonged (Ta-
ble 1). Fifty to ninety-three percent of cases and 69.3–
97.3% cases delivered within 48 hours and 7 days follow-
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Fig. 1. Birth weight and gestational age between the groups. Ga –
gestational age (weeks), bw – birth weight (grams), p<0.0001.
TABLE 2





<24 hours (%) 3.2 10.4
24–48 hours (%) 8.9 25.4
48–72 hours (%) 10.0 22.4






























Fig. 2. Latency period. Ga – gestational age (weeks), p=0.001.
ing rupture of membranes, respectively7,8. We found 58%
of our control group patients delivered within first 72
hours (Table 2). After two large, randomized controlled
trials, prolongation of latency period is believed to reduce
neonatal complications9,10. Thus, the American College
of Obstetricians and Gynecologists prepares guidelines
using prophylactic antibiotics in the expectant manage-
ment of PPROM to prolong pregnancy, reduce maternal
infectious morbidity and reduce infectious and gesta-
tional age-dependent neonatal morbidity. Corticosteroids
are recommended to administer in PPROM to reduce the
risk of neonatal prematurity related complications11. In
high-income countries, it is standard practice to give an-
tibiotics to women with preterm PPROM to delay birth
and reduce the risk of infection. In low and middle-in-
come settings, where some 2 million neonatal deaths oc-
cur annually due to complications of preterm birth or in-
fection, many women do not receive antibiotic therapy
for PPROM3. Chorioamnionitis is associated with 20–
40% of cases of early neonatal sepsis and pneumonia. Re-
cent data has suggested that exuberant fetal immune re-
sponse to intraamniotic infection is associated with
white matter brain injury and cerebral palsy12. We found
significant difference in reduction of chorioamnionitis
between the groups (14.25% vs. 36.3%), but no difference
in fetal brain ultrasound scan (6.7% vs. 4.2%). We ob-
served higher chorioamnionitis rate in the study group,
possibly due to longer latency period. Chorioamnionitis
is polymicrobial, primarily due to ascending colonization
or infection. Two-thirds of women with chorioamnionitis
have at least two isolates per specimen of amniotic fluid.
Regardless of gestational age, genital mycoplasmas are
the most common isolates. Genital mycoplasmas are
highly prevalent (>70%) in the lower genital tract and
their pathogenicity is controversial. We found them pres-
ent in 18% of patients in our control group (Table 1). For
this reason, some authors attribute their isolation from
patients with chorioamnionitis to contamination or colo-
nization from the lower tract, rather than a true infec-
tion. However, there is increasing support of their patho-
genicity, including induction of a robust inflammatory
response with clinical consequences for both mother and
neonate13. Measurement of maternal inflammatory re-
sponse (C-reactive protein >2 mg/dL) is not useful for
prediction of early intraamniotic infection14, but we found
it significantly different (11.8 vs. 21.74; p<0.0001). No-
vel proteomic biomarkers in the amniotic fluid or in the
maternal serum are under investigation in an attempt to
identify unique proteins diagnostic of subclinical chorio-
amnionitis14. Preliminary studies show promise in the di-
agnosis of early intraamniotic infection15. A regimen
with reasonable activity against the major pelvic patho-
gens should be used16. In our hospital there is no written
protocol for antibiotic prophylaxis in case of PPROM, but
a recommendation in administering a seven-day course
of antibiotic prophylaxis to all women with PPROM who
are being managed expectantly. Chemoprophylaxis we
used in last 5 years is showed in Figure 3. We found sig-
nificant difference in gestational age and birth weight
(Figure 2; p<0.0001) and latency period (Figure 3; p=
0.001) in study group. The preference is to give ampicil-
lin 2 g intravenously every six hours for 48 hours, fol-
lowed by amoxicillin (500 mg orally three times daily or
875 mg orally twice daily) for an additional five days with
one dose of azithromycin(one gram orally) upon admis-
sion. Ampicillin specifically targets group B streptococcus,
many aerobic gram-negative bacilli, and some anaerobes.
Azithromycin specifically targets genital mycoplasmas,
which can be important causes of chorioamnionitis in
this setting, and also provides coverage of Chlamydia
trachomatis17 which is an important cause of neonatal
conjunctivitis and pneumonitis. We found different treat-
ment options regarding the duration of PPROM (Figure
3) with significant difference in appearance in histologic
chorioamnionitis (Table 3; p<0.0001). Despite lack of
unified strategy, our study clearly documented that anti-
biotic prophylaxis leads to prolonged latency period in
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TABLE 3









Positive umbilicalcord blood culture (%) 8.8 14 13 10 0.046
Histologic – Chorioamnionitis (%) 34 33 44.5 38.6 <0.0001
Perinatal infections (%) 60 66.7 66.7 68 NS
Sepsis (%) 14 8.3 5.6 11.1 NS
Abnormal brain ultrasound (%) 7 7 0 10.5 NS 0.068
Fig. 3. Treatment option and duration of pprom, p<0.001.
PPROM. This is followed with prolongation of preg-
nancy, advanced fetal maturity and higher Apgar scores
in first and fifth minutes. Choice of prophylactic antibi-
otic regimen is at the moment in our country inconsis-
tent. This data support the need for unified antibiotic
prophylactic strategy. Recent Cochrane study which in-
cluded 22 trials, involving 6832 women and newborns
certify that routine prescription of antibiotics for women
with preterm rupture of membranes is associated with
prolongation of pregnancy and improvements in a num-
ber of short-term neonatal morbidities, but no signifi-
cant reduction in perinatal mortality18. Our study found
similar results (Table 1).
Conclusion
Antenatal antibiotics and corticosteroid therapies ha-
ve clear benefits and should be offered to all women with-
out contraindications. The antibiotic of choice is not
clear but co-amoxiclav should be avoided in women due
to increased risk of neonatal necrotizing enterocolitis18.
During conservative management, women should be mo-
nitored closely for placental abruption, infection, labor
and a non-reassuring fetal status. Women with PPROM
after 32 weeks of gestation should be considered for de-
livery, and after 34 weeks the benefits of delivery clearly
outweigh the risks19.
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ULOGA ANTIBIOTSKE PROFILAKSE U PRERANOM PRIJEVREMENOM PRSNU]U VODNJAKA
S A @ E T A K
Prerano prijevremeno prsnu}e vodenjaka (PRVP) javlja se u 3% svih trudno}a i odgovorno je za, ili je povezano sa
pribli`no jednom tre}inom prijevremeno ro|ene djece uzrokuju}i zna~ajni perinatalni morbiditet i smrt fetusa. Nedo-
no{~ad su vrlo osjetljiva na respiratorni distresni sindrom (RDS), intraventrikularno krvarenje (IVK), periventriku-
larnu leukomalaciju (PVL) te druge neurolo{ke bolesti, infekcije i nekrotiziraju}i enterokolitis (NEC). Korioamnionitis
se na temelju klini~kih kriterija javlja u oko 3-30% svih trudno}a kompliciranih PRVP-om. Cilj ovog istra`ivanja bio je
analizirati ulogu antibiotske profilakse za kona~ni neontalni ishod (tjelesnu te`inu, Apgar ocjenu, plu}ne komplikacije,
neurolo{ke komplikacije – abnormalni mo`dani ultrazvu~ni pregled prije otpusta iz bolnice, perinatalne infekcije) i
utvrditi mogu}nosti optimalanog antibiotskog lije~enja. Stoga smo retrospektivno analizirali trudno}e komplicirane
PRVP-om u posljednjih 5 godina u na{oj ustanovi, te u~inili pregled klini~kog tijeka i ishoda tih trudno}a lije~enih
profilakti~kim antibioticima i kortikosteroidima. Ukupno je bilo 324 nedono{~adi iz trudno}a koje su ispunile kriterije
za uklju~enje u na{e istra`ivanje, 190 u studijskoj grupi (trudnica je dobila empirijski antibiotik) i 134 u kontrolnoj
skupini (bez antibiotika). Prona{li smo zna~ajnu razliku u gestacijskoj dobi (p<0,0001), poro|ajnoj te`ini (p<0,0001),
Apgar ocjeni (p<0,0001), vrijednostima maj~inog C-reaktivnog proteina (p<0,0001) i razdoblju latencije (5,54 dana vs.
11.33days, p=0,001) izme|u skupina. Histolo{ki korioamnionitis je znatno ~e{}i u studijskoj skupini (14,2% vs. 36,3%,
p<0,0001). Prona{li smo zna~ajnu razliku u ishodima novoro|en~eta s obzirom na razli~itu antibiotsku profilaksu.
Antenatalna antibiotska i kortikosteroidna terapija imaju jasne prednosti i trebaju biti ponu|ene svim `enama u trud-
no}ama kompliciranim PRVP-om ukoliko nema kontraindikacija za njihovu primjenu.
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